

A Randomised Controlled Trial: Investigation of Radiotherapy Dose Inhomogeneity and Cosmetic Outcome in Patients with Early Breast Cancer

Submission date	Recruitment status	<input type="checkbox"/> Prospectively registered
10/01/2006	No longer recruiting	<input type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
17/02/2006	Completed	<input checked="" type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
22/08/2012	Cancer	

Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/a-study-to-see-if-intensity-modulated-radiotherapy-improves-cosmetic-appearance-for-breast-cancer-patients>

Contact information

Type(s)

Scientific

Contact name

Dr Charlotte Coles

Contact details

Oncology Centre
Box 193
Addenbrooke's Hospital
Hills road
Cambridge
United Kingdom
CB2 2QQ

Additional identifiers

Protocol serial number

N/A

Study information

Scientific Title**Acronym**

Cambridge IMRT

Study objectives

Does correction of dose homogeneity improve the cosmetic outcome following radiotherapy in patients with early breast cancer?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved by the Cambridge Research Ethics Committee on 04/02/03, reference number 03/017

Study design

Interventional, phase III, randomised controlled trial

Primary study design

Interventional

Study type(s)

Quality of life

Health condition(s) or problem(s) studied

Breast Cancer

Interventions

Patients are randomised to receive Intensity Modulated Radiation therapy (IMRT).

Control group will receive standard 2-dimensional radiation therapy.

Intervention Type

Other

Phase

Phase III

Primary outcome(s)

Breast shrinkage following radiotherapy

Key secondary outcome(s)

1. Acute skin reactions
2. Clinical assessment of late cosmetic effect
3. Patients quality of life

Completion date

31/03/2006

Eligibility

Key inclusion criteria

1. Age 18 years and above
2. Operable unilateral breast cancer (T1-3, N0-1, M0 at presentation)
3. Histological confirmation of invasive carcinoma
4. Complete macroscopic excision of tumour by breast conserving surgery
5. No history of contralateral breast cancer
6. Demonstration of off-axis dose inhomogeneities outside -5% and +7% of the prescribed dose using conventional 2-dimensional radiotherapy treatment plan
7. Patients consents to be part of the trial and availability for follow-up

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Female

Key exclusion criteria

1. Patients with advance or metastatic breast cancer
2. Patients who have had a mastectomy
3. Patients with bilateral breast cancer
4. Concomitant invasive malignancy (apart from Cervical Intra-epithelial Neoplasia [CIN] III uterine cervix and basal carcinoma of the skin), if other previous malignancies, must be disease-free for five years

Date of first enrolment

01/04/2003

Date of final enrolment

31/03/2006

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Oncology Centre
Cambridge
United Kingdom
CB2 2QQ

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust (UK)

ROR

<https://ror.org/04v54gj93>

Funder(s)

Funder type

Charity

Funder Name

Breast Cancer Campaign (London), grant reference number 2001:263 (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	baseline characteristics and dosimetry results	01/07/2009		Yes	No
Other publications	prospective analysis study	01/01/2012		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes